智通财经APP获悉，云顶新耀有限公司(01952)宣布，于2026年2月24日以线上虚拟会议形式举行的股东 特别大会顺利召开，会议所提呈的全部决议案均获股东正式通过。 此次各项决议案的高票通过，体现了投资者对公司战略方向及公司治理的认可，并将支持公司持续推进 商业化布局及长期发展战略。云顶新耀此前表示，与海森生物的合作有助于进一步提升现有商业化平台 运营效率，加快产品全生命周期及全渠道覆盖能力建设。 根据公告，本次股东特别大会批准、确认及追认了公司于2025年12月11日与海森生物签署的商业化服务 协议及其项下拟进行的相关交易，为公司后续商业化运营及业务推进提供支持。与此同时，大会还批准 了向公司管理层授出奖励安排，以及采纳2026年股份计划及相关授权限额等决议案。 ...

此次各项决议案的高票通过，体现了投资者对公司战略方向及公司治理的认可，并将支持公司持续推进 商业化布局及长期发展战略。云顶新耀此前表示，与海森生物的合作有助于进一步提升现有商业化平台 运营效率，加快产品全生命周期及全渠道覆盖能力建设。 云顶新耀有限公司(1952.HK)宣布，于2026年2月24日以线上虚拟会议形式举行的股东特别大会顺利召 开，会议所提呈的全部决议案均获股东正式通过。 根据公告，本次股东特别大会批准、确认及追认了公司于2025年12月11日与海森生物签署的商业化服务 协议及其项下拟进行的相关交易，为公司后续商业化运营及业务推进提供支持。与此同时，大会还批准 了向公司管理层授出奖励安排，以及采纳2026年股份计划及相关授权限额等决议案。 ...

Core Viewpoint - Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (Zhonghui Bio) reported significant growth in its first interim performance announcement post-IPO, driven by the commercialization of its core product, the quadrivalent influenza virus subunit vaccine, Hui Er Kang Xin, which has shown remarkable commercial success and a reduction in losses compared to the previous year [1][2]. Financial Performance - The company achieved a revenue of 71.12 million yuan in the first half of the year, representing a year-on-year increase of 918.91% [1]. - Sales costs decreased by 18.3% year-on-year, leading to a gross margin increase to 85.5% [1]. - Losses narrowed by 22% year-on-year, indicating ongoing improvements in profitability [1]. Product Development and Market Penetration - The quadrivalent influenza virus subunit vaccine, Hui Er Kang Xin, is the first and only approved quadrivalent influenza subunit vaccine in China, with a 100% pass rate for batch release since its commercialization began in September 2023 [2]. - The product's market penetration has expanded to 30 provinces, with over 1,100 collaborations with district-level disease control centers [2]. - The company is advancing its full population coverage strategy, with plans for a vaccine targeting infants aged 6-35 months expected to receive approval by Q3 2025 [2]. Research and Development Pipeline - The company has a diverse pipeline of 11 vaccines, structured in a gradient development model from late-stage to preclinical [4]. - The rabies vaccine is in the final clinical stage, having completed Phase I trials with promising safety results [3]. - The company is also progressing in other high-demand areas, including the 23-valent pneumococcal polysaccharide vaccine and recombinant RSV vaccine, with various clinical trials underway [4]. Global Expansion Strategy - The company is building its international sales network, with plans to enter markets in Indonesia, Thailand, Uruguay, Canada, Singapore, Mexico, and Hong Kong by 2026 [5]. - In 2024, the company received registration in Macau and is progressing with registration in the Philippines [5]. - The company aims to leverage seasonal differences in flu outbreaks across regions to optimize production capacity [5]. Future Outlook - With the anticipated approval of the low-age indication for the influenza vaccine and the rabies vaccine entering Phase III clinical trials, the company is positioned to strengthen its competitive advantage in the high-growth vaccine sector [5].